Table 2.

Progression-free survival and overall survival of patient subgroup

	Control group (n = 43)	Experimental group (n = 38)	p-value	HR (95% CI)
Progression free survival
Progression or death (%)	31 (72.1)	28 (73.7)
At 6 month PFS rate (95% CI)	0.32 (0.18–0.47)	0.29 (0.15–0.45)
At 12 month PFS rate (95% CI)	0.24 (0.11–0.40)	0.15 (0.04–0.32)
At 24 month PFS rate (95% CI)	0.12 (0.03–0.29)	N/A
Median PFS time in months (95% CI)	2.66 (1.74–4.40)	2.30 (1.74–3.29)	0.679	1.12 (0.67–1.87)
Overall survival
Death (%)	21 (48.8)	13 (34.2)
At 6 month OS rate (95% CI)	0.60 (0.42–0.74)	0.83 (0.64–0.93)
At 12 month OS rate (95% CI)	0.46 (0.28–0.62)	0.75 (0.55–0.88)
At 24 month OS rate (95% CI)	0.25 (0.08–0.46)	0.14 (0.01–0.44)
Median OS time in months (95% CI)	7.69 (5.16–22.67)	17.22 (12.19–21.68)	0.473	0.78 (0.39–1.58)

HR (95% CI) were obtained from the Cox proportional hazards regression models. Survival rates and median time were estimated from Kaplan-Meier analyses.

HR hazard ratio; CI confidence interval; PFS progression-free survival; OS overall survival